A 57-year-old transgender woman with HIV and hepatitis C virus (HCV) is seen in clinic for a follow-up evaluation. She has documented cirrhosis based on results from hepatic elastography. She received treatment for hepatitis C virus (HCV) with glecaprevir-pibrentasvir about 1 year ago and had an undetectable HCV RNA level 12 weeks after completing treatment.
Which one of the following is recommended for hepatocellular carcinoma (HCC) screening for this woman?
Sign In or Register Progress Not Saved!
Since you are not signed in, your progress won't be saved.
Since you are not signed in, your progress won't be saved.
Question Last Updated
April 6th, 2024
April 6th, 2024
Steps to Acquire CE for this Question Bank Topic:
1
Answer
Answer all questions
2
Score 80%+
Answer correctly
3
Claim CE
Choose CNE or CME
4
Give Feedback
Complete survey
5